News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,272 Results
Type
Article (87413)
Company Profile (739)
Press Release (770102)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232768)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91175)
Employer Resources (205)
FDA (18253)
Job Trends (17422)
News (396850)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (120)
Alliances (56794)
ALS (153)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (312)
Approvals (18366)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (538)
Cancer (4275)
Cardiovascular disease (301)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (760)
Cervical cancer (29)
Clinical research (76103)
Collaboration (1603)
Company closure (4)
Compensation (990)
Complete response letters (64)
COVID-19 (2927)
CRISPR (85)
C-suite (732)
Cystic fibrosis (143)
Data (5407)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (340)
Diagnostics (6976)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (197)
Earnings (97996)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132799)
Executive appointments (824)
FDA (20617)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1269)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (931)
Government (5323)
Grass and pollen (4)
Guidances (276)
Healthcare (20777)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (80)
Infectious disease (3146)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (582)
Lymphoma (331)
Machine learning (41)
Management (66)
Manufacturing (714)
MASH (159)
Medical device (14421)
Medtech (14451)
Mergers & acquisitions (22742)
Metabolic disorders (1062)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (79)
Neuroscience (2891)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (520)
Opinion (325)
Ovarian cancer (150)
Pain (153)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (33)
Patents (394)
Patient recruitment (414)
Peanut (56)
People (66277)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23595)
Phase 2 (33119)
Phase 3 (24813)
Pipeline (4280)
Policy (283)
Postmarket research (3544)
Preclinical (10586)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (278)
Rare diseases (792)
Real estate (7422)
Recruiting (80)
Regulatory (28227)
Reports (63)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (998)
Venture capital (91)
Weight loss (338)
Women's health (71)
Worklife (22)
Date
Today (1)
Last 7 days (472)
Last 30 days (1734)
Last 365 days (25244)
2026 (2379)
2025 (25543)
2024 (34032)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51120)
Australia (9002)
California (9719)
Canada (2473)
China (1055)
Colorado (306)
Connecticut (389)
Delaware (295)
Europe (116899)
Florida (1256)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (652)
India (56)
Indiana (445)
Iowa (21)
Japan (338)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1256)
Massachusetts (7303)
Michigan (244)
Minnesota (452)
Mississippi (5)
Missouri (78)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2549)
New Mexico (29)
New York (2550)
North Carolina (1410)
North Dakota (9)
Northern California (4770)
Ohio (257)
Oklahoma (18)
Oregon (51)
Pennsylvania (1869)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3750)
Tennessee (58)
Texas (1358)
United States (33778)
Utah (209)
Vermont (1)
Virginia (168)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (82)
858,272 Results for "telesis bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
May 28, 2025
·
3 min read
Biotech Beach
Telesis Bio Announces Reverse Stock Split - May 06, 2024
Telesis Bio Inc., a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, announced that it will effect a 1-for-18 reverse stock split of its common stock.
May 6, 2024
·
4 min read
Business
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Telesis Bio Inc. today announced certain preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023.
February 26, 2024
·
5 min read
Business
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023.
March 28, 2024
·
9 min read
Business
Telesis Bio Reports Third Quarter 2023 Financial Results
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023.
November 13, 2023
·
7 min read
Business
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
Telesis Bio today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes.
November 7, 2023
·
1 min read
Business
Telesis Bio Reports Second Quarter 2023 Financial Results
Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, reported financial results for the second quarter of 2023.
August 10, 2023
·
7 min read
Biotech Beach
Telesis Bio Secures Financing of $28.0 Million
Telesis Bio Inc. announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock.
May 31, 2023
·
5 min read
Business
Telesis Bio Appoints William J. Kullback Chief Financial Officer
Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023.
August 29, 2023
·
3 min read
Biotech Beach
Telesis Bio to Present at Jefferies Healthcare Conference 2023
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.
June 8, 2023
·
2 min read
1 of 85,828
Next
